BOT has announced that its Atopic Dermatitis (AD) Phase 2 clinical study did not reach its primary or secondary endpoints. We downgrade our SPEC BUY recommendation to a HOLD with a reduced-price target of $0.06 (from $0.29).
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.